Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Chosa Oncology AB: CHOSA Oncology AB's abstract Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer accepted at 2023 ASCO Annual Meeting

Download the release

CHOSA Oncology a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP[®] companion diagnostics for personalized cancer care, today announced that an abstract with the title `Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer' has been accepted for a poster presentation at the world's biggest and prestigious cancer conference  American Society of Clinical Oncology (ASCO) Annual Meeting in June 2023 in Chicago, USA.

CEO Peter Buhl will present the data at the ASCO meeting taking place June 2-6 online and in person at the McCormick Place in Chicago. The poster shows the final data from a phase 2 study evaluating the ability of the DRP[®] companion diagnostic for cisplatin to prospectively identify patients with metastatic breast cancer that are likely to respond to treatment with LiPlaCis[®], a targeted liposomal formulation of cisplatin. The study was  conducted  in collaboration with investigators at hospitals in Denmark. CHOSA Oncology has inlicensed worldwide rights to the LiPlaCis program and its DRP which together is named iCIP™.

The poster presentation details are as follows:

Poster Title: "Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer."
Authors: Nielsen, D., Jakobsen, E,H., Langkjer, S.T., Danoe, H., Balslev, E., Knoop, A., … Lassen, U.N.
Abstract Number: 3130
Session Title: Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology
Date and Time: 6/3/2023, 8:00 AM-11:00 AM local time

This disclosure contains information that Chosa Oncology AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 11-04-2023 13:00 CET.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.